Frank Qin is an associate in the Goodwin’s Life Sciences group and a member of the firm’s Intellectual Property Transactions and Strategies practice. Frank represents life science companies in intellectual property-driven transactions, including license agreements, collaboration agreements, co-development agreements, sponsored research agreements, clinical trial agreements, services agreements, material transfer agreements, manufacturing agreements, supply agreements, and distribution agreements. He also advises clients throughout their corporate lifecycles on the intellectual property aspects of corporate transactions, including mergers and acquisitions, financings, asset sales, and royalty monetization deals. He joined Goodwin in 2021.
Representative Matters
Frank’s recent representative experience, among others, includes:
- ARTBIO in its research collaboration with Fog Pharmaceuticals for development of a new class of alpha radioligand therapeutics that will maximize efficacy and transform patient outcomes
- Full-Life Technologies in its licensing agreement with SK Biopharmaceuticals for development and commercialization of innovative anti-cancer drugs utilizing Full-Life’s NTSR1-targeting Radionuclide Drug Conjugate program FL-091. The deal has a $571.5 million overall value
- Flagship Pioneering in its research collaboration with Novo Nordisk and Metaphore Biotechnologies for development of multitarget therapeutics leveraging GLP-1R and related biology for obesity management
- Allogene Therapeutics in its licensing agreement with Arbor Biotechnologies for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease
- Isomorphic Labs in its strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets. The deal included a $37.5 million upfront payment and $1.2 billion overall deal value
- Flagship Pioneering in its research collaboration with Novo Nordisk and Omega Therapeutics for development of an epigenomic controller designed to enhance metabolic activity as part of a new treatment approach for obesity management
- Oak Hill Bio in its spin-out from Takeda Pharmaceutical with Phase II clinical candidates for neonatology and rare disease therapeutics, specifically OHB-607 for extreme preterm births and OHB-101 for rare autoimmune diseases
- Bicara Therapeutics in its $165 million Series C financing
- Rapport Therapeutics in its $150 million Series B financing
- Bicara Therapeutics in its $108 million Series B financing
- Rapport Therapeutics in its $100 million Series A financing
- Alladapt Immunotherapeutics in its $119 million Series D financing
- Garuda Therapeutics in its $62 million Series B financing
Areas of Practice
Professional Experience
While attending law school, Frank served as a judicial intern at the U.S. District Court for the Middle District of North Carolina, participated in UNC’s Consumer Financial Transactions Clinic, and served as an Articles Editor for the North Carolina Law Review.
Prior to law school, Frank worked at Epic Systems, an electronic health record software company based in Verona, WI, in the Technical Services role for inpatient and outpatient pharmacy applications.
Professional Activities
Frank is a member of the Boston Bar Association.
Credentials
Education
JD2021
The University of North Carolina School of Law
(with honors)
BS2012
Johns Hopkins University
Admissions
Bars
- Massachusetts
- U.S. Patent and Trademark Office (USPTO)
Publications
Author, “The Debilitating Scope of Care Coordination Under HIPAA,” 98 N.C. L. REV. 1395, 2020